| Ytd | 4.61% | |
| 1y | -29.96% |
| Open | 0.83 | Prev Close | 0.84 | Low | 0.75 | High | 0.90 | Mkt Cap | 58.38M |
| Vol | 18.98M | Avg Vol | 20.76M | EPS | -0.64 | P/E | N/A | Forward P/E | -1.18 |
| Beta | 1.93 | Short Ratio | 10.47 | Inst. Own | 12.36% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 0.50 | 200-d Avg | 0.80 | 1yr Est | 11.50 |
PDSB News
Gainers DataMEDS AI (NASDAQ:MEDS) shares increased by 354.9% to $7.37 during Wednesday's regula
Shares of PDS Biotechnology Corp (NASDAQ: PDSB) are trading sharply higher Tuesday afternoon, extend
Gainers PDS Biotechnology (NASDAQ:PDSB) shares rose 63.7% to $0.65 during Tuesday's regular ses
Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) shares moved upwards by 39.3% to $1.56 during Tuesday
Gross Proceeds of $11.3 Million at Initial Closing Transaction Led by Dr. Patrick Soon-Shiong, Found
Gainers AEON Biopharma (AMEX:AEON) stock moved upwards by 8.9% to $0.32 during Thursday's after
PDS Biotechnology Corporation (NASDAQ: PDSB - Get Free Report) was the target of some unusual option
HC Wainwright & Co. analyst Joseph Pantginis maintains PDS Biotechnology (NASDAQ:PDSB) with a
Gainers Indaptus Therapeutics (NASDAQ:INDP) stock increased by 46.7% to $1.79 during Tuesday's
U.S. stocks fell Tuesday as health care lagged, while energy gained. ABM beat estimates; oil rose, a
U.S. stocks fell Tuesday, led by a 450-point Dow drop; health care slid while energy rose. NFIB opti
Dr. Soon-Shiong will Join PDS Biotech's Board of Directors PDS Biotech Plans to Progress Development
HC Wainwright & Co. analyst Joseph Pantginis reiterates PDS Biotechnology (NASDAQ:PDSB) with
On August 13, 2026, Lars Boesgaard submitted his resignation, effective as of September 12, 2026, as
HC Wainwright & Co. analyst Joseph Pantginis maintains PDS Biotechnology (NASDAQ:PDSB) with a
PDS Biotechnology (NASDAQ:PDSB) reported quarterly losses of $(0.18) per share which missed the anal
PRINCETON, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PD
PDS Biotechnology Corporation (NASDAQ:PDSB) shares have fallen by about 67% on Tuesday as the compan
PDS Biotechnology stock tanks as the company refocuses resources on its PDS0301 metastatic colorecta
Gainers Neuronetics (NASDAQ:STIM) shares moved upwards by 34.1% to $2.91 during Tuesday's regul
"Dear Fellow Shareholders,Over the past several months, our Board of Directors and management te
PRINCETON, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PD
Up to $50,000,000 Common StockWe have entered into the sales agreement (the "Sales Agreement"
PDS Biotechnology (PDSB) appears to have found support after losing some value lately, as indicated
PDS Biotechnology NASDAQ: PDSB reported a smaller first-quarter loss and highlighted changes to its
PDS Biotechnology Corporation (PDSB) Q1 2026 Earnings Call Transcript
PDS Biotechnology (NASDAQ:PDSB) reported quarterly losses of $(0.13) per share which beat the analys
Investor Webcast Scheduled for 8:00 am ET PRINCETON, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- PDS Biot
PRINCETON, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS
HC Wainwright & Co. analyst Joseph Pantginis reiterates PDS Biotechnology (NASDAQ:PDSB) with
PDS Biotechnology says Phase 2 data show higher response rates and survival trends in colorectal can
78% Objective Response Rate (ORR) with PDS01ADC; Parallel trial without PDS01ADC had 35% ORR 2-year
78% Objective Response Rate (ORR) with PDS01ADC; Parallel trial without PDS01ADC had 35% ORR 2-year
PDS Biotechnology Corporation (PDSB) Q4 2025 Earnings Call Transcript
PDS Biotechnology (NASDAQ:PDSB) reported quarterly losses of $(0.14) per share which beat the analys
PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late
Full Year 2025 Financial ResultsNet loss for the year ended December 31, 2025, was approximately $34
Filed Phase 3 Amendment Incorporates PFS as Interim Primary Endpoint Expected to Shorten Trial Durat
PRINCETON, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“P
https://www.sec.gov/ix?doc=/Archives/edgar/data/1472091/000114036126007478/ef20067044_8k.htm#fact-id
PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a lat
Enables Potential Shorter Time to Accelerated Approval of PDS0101 in HPV16-positive Head and Neck Ca
NCI-Led Study Shows Median PFS of 9.6 Months Results Presented at AACR Special Conference on Innovat
NCI-Led Study Shows Median PFS of 9.6 Months Results Presented at AACR Special Conference on Innova
PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late